STOCK TITAN

MDGL insiders sold 153,648 shares via 10b5-1; proposed $46.4M sale disclosed

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 129,172 shares of Common stock to be effected through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $46,372,748. The shares were acquired by the filer through the exercise of stock options on 08/13/2025 and payment was in cash.

The filing also lists multiple recent Rule 10b5-1 sales by two insiders, Rebecca Taub and Paul A. Friedman, showing combined sales of 153,648 shares in the past three months that generated approximately $54,457,408 in gross proceeds. The form includes the standard representation that the seller does not possess undisclosed material adverse information.

Positive

  • None.

Negative

  • Planned sale of 129,172 shares acquired by option exercise with an aggregate market value of $46,372,748 to be sold via Morgan Stanley on NASDAQ.
  • Multiple 10b5-1 insider sales totaling 153,648 shares in the past three months, generating approximately $54,457,408 in gross proceeds (Rebecca Taub and Paul A. Friedman combined).

Insights

TL;DR: Routine Form 144 for an insider sale by option exercise; multiple recent 10b5-1 sales generated sizable gross proceeds.

The filing documents a planned sale of 129,172 shares acquired by exercise of options on 08/13/2025, to be sold through Morgan Stanley on NASDAQ for an aggregate market value of $46,372,748. The record of recent 10b5-1 transactions shows combined insider sales of 153,648 shares producing roughly $54.46M in gross proceeds over the past three months. These are factual disclosures of executed and proposed sales under Rule 144 and 10b5-1; they reflect liquidity events by insiders rather than operating results.

TL;DR: Disclosure follows standard Rule 144 and 10b5-1 formats with the usual certification about non-public material information.

The Form 144 identifies the seller, broker (Morgan Stanley Smith Barney LLC Executive Financial Services), the class of security, and the acquisition method (exercise of stock options) with cash payment. The document also details multiple 10b5-1 sales by named insiders with itemized dates, amounts, and gross proceeds. The filing contains the typical representation that the filer does not possess material undisclosed information, consistent with regulatory requirements for these notices.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Madrigal Pharmaceuticals (MDGL) disclose?

The form reports a proposed sale of 129,172 shares of Common stock to be sold through Morgan Stanley on NASDAQ with an aggregate market value of $46,372,748.

How were the 129,172 shares acquired according to the filing?

The shares were acquired on 08/13/2025 by the exercise of stock options and payment was made in cash.

Who executed recent 10b5-1 sales and what were the totals?

The filing lists 10b5-1 sales by Rebecca Taub (76,564 shares) and Paul A. Friedman (77,084 shares), combined 153,648 shares, generating about $54,457,408 in gross proceeds.

Through which broker will the proposed sale be executed?

The proposed sale lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and indicates the sale will be on NASDAQ.

Does the filer certify possession of undisclosed material information?

The Form 144 includes the standard representation that the person selling the securities does not know any material adverse information about the issuer that has not been publicly disclosed.
Madrigal Pharmac

NASDAQ:MDGL

MDGL Rankings

MDGL Latest News

MDGL Latest SEC Filings

MDGL Stock Data

13.60B
20.97M
7.7%
107.92%
18.16%
Biotechnology
Pharmaceutical Preparations
Link
United States
WEST CONSHOHOCKEN